#EULAR2024 Cutaneous #lupus is variable & can be difficult to treat. Promising post-hoc data frm Phase 2 RCT showing Deucravacitinib (Tyk2-i) led to improvement & sustained CLASI-50 response in all subtypes (ACLE, SCLE, Chonic and Discoid) @RheumNow #EULARBEST https://t.co/ArAzdLYiYY

• https://twitter.com/Yuz6Yusof/status/1801129647603658984/photo/1
• https://twitter.com/Yuz6Yusof/status/1801129647603658984/photo/1

#EULAR2024 OP0043 Data from UK BILAG-BR registry showed in n>100 patients w neuropsychiatric #lupus (NPSLE), over 2/3 improved with rituximab. NPSLE tended to occur with other #SLE features and with high level of organ damage @RheumNow https://t.co/q5olZgr6Pt

• https://twitter.com/Yuz6Yusof/status/1801123910437482766/photo/1

I’ve always thought new RA meds get prescribed to the most risky patients, and therefore you see more adverse events. Turns out it’s marginally true - maybe out to five years. Worth being careful of judging new meds too early! #EULAR2024 OP0114 @karolinskainst @RheumNow https://t.co/Q8dIHiIYQk

• https://twitter.com/drdavidliew/status/1801182711882875027/photo/1
• https://twitter.com/drdavidliew/status/1801182711882875027/photo/1
• https://twitter.com/drdavidliew/status/1801182711882875027/photo/1
• https://twitter.com/drdavidliew/status/1801182711882875027/photo/1

#EULARBest OP0156- validation & prevalence of D2T RA Data from @BrighamResearch BRASS In this cohort, the #EULAR definition of D2TRA correctly identified a subset of RA pts who have not achieved low disease activity despite multiple b/ts DMARD treatments #EULAR2024 @RheumNow

OP0137 is comparative analysis of clinical efficacy & drug retention of b/tsDMARDs >1/2 D2T RA pts starting JAKi, RTX, IL-6Ri, or TNFi, but ~1/3 w abatacept, achieved remission or low disease activity in 6m & maintained consistent drug retention for 2yrs @RheumNow #EULAR2024

RheumNow’s expanded coverage of the #EULAR2024 annual meeting is sponsored in part by Bristol Myers Squibb and UCB. All content is chosen by RheumNow & our Faculty.

Synovial tissue specimens were processed for H&E-based semiquantitative synovitis quantification (KSS) in biopsies in PsA. KSS was significantly higher in cs/b-DMARDs resistant patients than naive PsA(p<0.0001) and PsA in remission/LDA (p<0.0001). KSS directly correlated with… https://t.co/cHIw8zRByK https://t.co/vppmG7JwC8

• https://twitter.com/i/web/status/1801184323137126743
• https://twitter.com/synovialjoints/status/1801184323137126743/photo/1
• https://twitter.com/synovialjoints/status/1801184323137126743/photo/1

In a Swedish-Danish cohort study on patients with PsA, treatment with TNFi was associated with a small increased risk of NMSC and with non-significant numeric risk increases for both BCC and SCC compared with bDMARD naïve #EULAR2024 Abstract 0150 @RheumNow https://t.co/vC4pgSKmfY

• https://twitter.com/synovialjoints/status/1801180459742671358/photo/1
• https://twitter.com/synovialjoints/status/1801180459742671358/photo/1

Is it worthwhile delaying MTX start for a month in RA, to vaccinate effectively? VACIMRA (multicentre 🇫🇷) showed it marginally improves pneumococcal vaccine immunogenicity, persisting to 1y, no extra pred needed. I’ll admit, I’m still not game! #EULAR2024 OP0140 @RheumNow https://t.co/58qJxki8ov

• https://twitter.com/drdavidliew/status/1801179511561785657/photo/1
• https://twitter.com/drdavidliew/status/1801179511561785657/photo/1
• https://twitter.com/drdavidliew/status/1801179511561785657/photo/1
• https://twitter.com/drdavidliew/status/1801179511561785657/photo/1

How can we predict the 1/3 of palindromic rheumatism patients who will go on to develop persistent inflamm arthritis? Easy to use score derived from 15y data from @UniversityLeeds - can exclude the low-risk so they don’t need to be followed. #EULAR2024 OP0127 @RheumNow https://t.co/gB0FpUPOFC

• https://twitter.com/drdavidliew/status/1801176356224680405/photo/1
• https://twitter.com/drdavidliew/status/1801176356224680405/photo/1
• https://twitter.com/drdavidliew/status/1801176356224680405/photo/1

OP0131 on occurrence & predictors of #DMARD treatment failure in #RA 8% of pts failed ≥3 b/tsDMARDs with ~4yrs to failure In pts starting first b/tsDMARD, up to 25% fail ≥2 b/tsDMARDs in 3yrs Risk of fulfilling EULAR D2T criterion 1 ➡️ 2.3% in first 5yrs @RheumNow #EULAR2024

🗣️Abstract session on difficult-to-treat #RA kicks off with OP0118 on predictors of D2T RA 📈Female sex, high joint count, erosions, pulmonary #comorbidities, depression & fatigue assoc with D2T RA 💊MTX after start of advanced therapy protective of D2T RA @RheumNow #EULAR2024

#EULAR2024 OP0076 UK multicentre cohort study showed rituximab was effective in systemic features of #Sjogren in children & adults. One in 6 lost response in subsequent cycle due to antidrug antibodies. Humanised or type 2 antiCD20Ab in the future could improve this @RheumNow https://t.co/duYpr2yKGB

• https://twitter.com/Yuz6Yusof/status/1801119512407801957/photo/1

#EULAR2024 OP0077 How can we improve Bcell killing and does deep depletion matter? Biomarkers from RCT showed Obinutuzumab led to profound circulatory depletion in #lupus nephritis & those w sustained depletion had better complete renal response than those who didn’t @RheumNow https://t.co/2KTZBR2njk

• https://twitter.com/Yuz6Yusof/status/1801116419540586582/photo/1